口服避孕药与全身性高血压之间的关系:系统回顾与随机临床试验干预的统计比较

IF 1.5 Q3 OBSTETRICS & GYNECOLOGY
Ingrid Soares de Souza , Gabriel Zorello Laporta , Juliana Zangirolami-Raimundo , Isabel Cristina Esposito Sorpreso , Heloisa Carla Lopes Silva dos Santos , José Maria Soares Júnior , Rodrigo Daminello Raimundo
{"title":"口服避孕药与全身性高血压之间的关系:系统回顾与随机临床试验干预的统计比较","authors":"Ingrid Soares de Souza ,&nbsp;Gabriel Zorello Laporta ,&nbsp;Juliana Zangirolami-Raimundo ,&nbsp;Isabel Cristina Esposito Sorpreso ,&nbsp;Heloisa Carla Lopes Silva dos Santos ,&nbsp;José Maria Soares Júnior ,&nbsp;Rodrigo Daminello Raimundo","doi":"10.1016/j.eurox.2024.100307","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>In the WHO eligibility criteria, there is agreement that hypertensive women taking Oral Contraceptive Hormonal Combined (OCHC) may be at increased risk of cardiovascular disease. The risk-to-benefit ratio hinges on the severity of the condition. While a mild increase in blood pressure is a common occurrence in consumers of OCHC, the potential for developing high blood pressure exists during oral contraceptive use. Consequently, there is a possibility of increased cardiovascular risk, with limited available data on this issue.</p></div><div><h3>Objective</h3><p>To evaluate the potential effects of OCHC on blood pressure through a systematic review with statistical analysis of existing randomized controlled trials.</p></div><div><h3>Method</h3><p>This systematic review with statistical comparison adheres to the recommendations outlined in the PRISMA (Principal Reporting Items for Systematic Reviews and Meta-analyses) guidelines. The analysis strategy involves comparing the mean difference in blood pressure change according to the type of treatment, in addition to the calculation of clinically relevant outcomes (CRO).</p></div><div><h3>Results</h3><p>Our findings suggest a clinically relevant outcome related to the increase in blood pressure in users of ethinyl estradiol combined with gestodene in a cyclic regimen over 6 months. Conversely, a decrease in blood pressure was observed among users of ethinyl estradiol combined with chlormadinone over 24 months of usage.</p></div><div><h3>Conclusion</h3><p>While our study found minor variations in blood pressure across varying forms of oral contraceptives, these differences are not significant enough to warrant specific clinical recommendations. However, the results suggest that individuals with hypertension should exercise caution with ethinyl estradiol, particularly when administered cyclically alongside gestodene, due to the potential risk of increased blood pressure. Additionally, the use of oral contraceptives containing ethinyl estradiol paired with chlormadinone acetate or ethinyl estradiol combined with drospirenone may be more suitable for individuals at a high risk of developing hypertension.</p></div>","PeriodicalId":37085,"journal":{"name":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590161324000279/pdfft?md5=c1cd82fd1555743c1b7b2a5b0019130c&pid=1-s2.0-S2590161324000279-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Association between the use of oral contraceptives and the occurrence of systemic hypertension: A systematic review with statistical comparison between randomized clinical trial interventions\",\"authors\":\"Ingrid Soares de Souza ,&nbsp;Gabriel Zorello Laporta ,&nbsp;Juliana Zangirolami-Raimundo ,&nbsp;Isabel Cristina Esposito Sorpreso ,&nbsp;Heloisa Carla Lopes Silva dos Santos ,&nbsp;José Maria Soares Júnior ,&nbsp;Rodrigo Daminello Raimundo\",\"doi\":\"10.1016/j.eurox.2024.100307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>In the WHO eligibility criteria, there is agreement that hypertensive women taking Oral Contraceptive Hormonal Combined (OCHC) may be at increased risk of cardiovascular disease. The risk-to-benefit ratio hinges on the severity of the condition. While a mild increase in blood pressure is a common occurrence in consumers of OCHC, the potential for developing high blood pressure exists during oral contraceptive use. Consequently, there is a possibility of increased cardiovascular risk, with limited available data on this issue.</p></div><div><h3>Objective</h3><p>To evaluate the potential effects of OCHC on blood pressure through a systematic review with statistical analysis of existing randomized controlled trials.</p></div><div><h3>Method</h3><p>This systematic review with statistical comparison adheres to the recommendations outlined in the PRISMA (Principal Reporting Items for Systematic Reviews and Meta-analyses) guidelines. The analysis strategy involves comparing the mean difference in blood pressure change according to the type of treatment, in addition to the calculation of clinically relevant outcomes (CRO).</p></div><div><h3>Results</h3><p>Our findings suggest a clinically relevant outcome related to the increase in blood pressure in users of ethinyl estradiol combined with gestodene in a cyclic regimen over 6 months. Conversely, a decrease in blood pressure was observed among users of ethinyl estradiol combined with chlormadinone over 24 months of usage.</p></div><div><h3>Conclusion</h3><p>While our study found minor variations in blood pressure across varying forms of oral contraceptives, these differences are not significant enough to warrant specific clinical recommendations. However, the results suggest that individuals with hypertension should exercise caution with ethinyl estradiol, particularly when administered cyclically alongside gestodene, due to the potential risk of increased blood pressure. Additionally, the use of oral contraceptives containing ethinyl estradiol paired with chlormadinone acetate or ethinyl estradiol combined with drospirenone may be more suitable for individuals at a high risk of developing hypertension.</p></div>\",\"PeriodicalId\":37085,\"journal\":{\"name\":\"European Journal of Obstetrics and Gynecology and Reproductive Biology: X\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2024-04-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590161324000279/pdfft?md5=c1cd82fd1555743c1b7b2a5b0019130c&pid=1-s2.0-S2590161324000279-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Obstetrics and Gynecology and Reproductive Biology: X\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590161324000279\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Obstetrics and Gynecology and Reproductive Biology: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590161324000279","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:在世界卫生组织的资格标准中,一致认为服用口服激素避孕药(OCHC)的高血压妇女可能会增加罹患心血管疾病的风险。风险与收益的比率取决于病情的严重程度。虽然血压轻度升高是 OCHC 使用者的常见现象,但在口服避孕药期间也有可能患上高血压。通过对现有随机对照试验进行系统回顾和统计分析,评估 OCHC 对血压的潜在影响。方法本系统回顾和统计比较遵循 PRISMA(系统回顾和元分析的主要报告项目)指南的建议。分析策略包括根据治疗类型比较血压变化的平均差异,以及计算临床相关结果(CRO)。结果我们的研究结果表明,炔雌醇联合孕二烯循环治疗 6 个月后,临床相关结果与血压升高有关。结论虽然我们的研究发现不同形式的口服避孕药在血压方面存在微小差异,但这些差异并不显著,不足以提出具体的临床建议。然而,研究结果表明,由于血压升高的潜在风险,高血压患者应谨慎使用炔雌醇,尤其是周期性与孕二烯酮同时使用时。此外,炔雌醇与醋酸氯地孕酮或炔雌醇与屈螺酮合用的口服避孕药可能更适合高血压高危人群。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between the use of oral contraceptives and the occurrence of systemic hypertension: A systematic review with statistical comparison between randomized clinical trial interventions

Introduction

In the WHO eligibility criteria, there is agreement that hypertensive women taking Oral Contraceptive Hormonal Combined (OCHC) may be at increased risk of cardiovascular disease. The risk-to-benefit ratio hinges on the severity of the condition. While a mild increase in blood pressure is a common occurrence in consumers of OCHC, the potential for developing high blood pressure exists during oral contraceptive use. Consequently, there is a possibility of increased cardiovascular risk, with limited available data on this issue.

Objective

To evaluate the potential effects of OCHC on blood pressure through a systematic review with statistical analysis of existing randomized controlled trials.

Method

This systematic review with statistical comparison adheres to the recommendations outlined in the PRISMA (Principal Reporting Items for Systematic Reviews and Meta-analyses) guidelines. The analysis strategy involves comparing the mean difference in blood pressure change according to the type of treatment, in addition to the calculation of clinically relevant outcomes (CRO).

Results

Our findings suggest a clinically relevant outcome related to the increase in blood pressure in users of ethinyl estradiol combined with gestodene in a cyclic regimen over 6 months. Conversely, a decrease in blood pressure was observed among users of ethinyl estradiol combined with chlormadinone over 24 months of usage.

Conclusion

While our study found minor variations in blood pressure across varying forms of oral contraceptives, these differences are not significant enough to warrant specific clinical recommendations. However, the results suggest that individuals with hypertension should exercise caution with ethinyl estradiol, particularly when administered cyclically alongside gestodene, due to the potential risk of increased blood pressure. Additionally, the use of oral contraceptives containing ethinyl estradiol paired with chlormadinone acetate or ethinyl estradiol combined with drospirenone may be more suitable for individuals at a high risk of developing hypertension.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.20
自引率
0.00%
发文量
31
审稿时长
58 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信